Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RECOGNISED

Financiado

Cerrado

Retinal and cognitive dysfunction in type 2 diabetes unraveling the common path...

Retinal and cognitive dysfunction in type 2 diabetes unraveling the common pathways and identification of patients at risk of dementia In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a new long-term diabetic co-morbid complication with dramatic consequences for... ver más

31/12/2024

FUNDACIO HOSPITAL...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FUNDACIO HOSPITAL UNIVERSITARI VALL HEBRON -... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 33M€

Fecha límite participación Sin fecha límite de participación.

Ver 24 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-BHC-01-2019: Understanding causative mechanisms...

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

24 Participantes

FUNDACIO HOSPITAL UNIVERSITA...

950.41K€ | Lider

BELSPO

35.00K€ | Participante

UMIL

250.00K€ | Participante

FONDAZIONE G.B.BIETTI PER LO...

97.75K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2017-91910-EXP DIABETES MELLITUS TIPO 2: MARCADORES DE DAÑO CENTRAL IN VIVO... 85K€ Cerrado

IPACBIS Identifying preclinical Alzheimer s disease in the community... 158K€ Cerrado

VERDAD A blood based biomarker identifying early Alzheimer Disease... 3M€ Cerrado

SAF2011-30578 IDENTIFICACION DE RUTAS METABOLICAS EN LA NEURODEGENERACION... 157K€ Cerrado

PDC2021-121350-I00 BIOMARCADORES PARA EL DIAGNOSTICO PRECOZ DEL DECLIVE COGNITI... 150K€ Cerrado

PSI2016-75484-R NUEVAS HERRAMIENTAS DIAGNOSTICAS DEL DETERIORO COGNITIVO: UN... 62K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2019-11-21
Fecha Fin: 2024-12-31

Líder del proyecto

FUNDACIO HOSPITAL UNIVERSITARI VALL HEBRON -... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 33M€

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a new long-term diabetic co-morbid complication with dramatic consequences for patients and their families and a significant impact for healthcare systems. At present there are no reported phenotypic indicators or reliable tests to identify T2D patients at risk of developing dementia. Since the retina is ontogenically a brain-derived tissue, we propose that the evaluation of retinal parameters related to either neurodegeneration or microvascular disease will be robust and valuable biomarkers to identify those T2D patients at higher risk of developing cognitive impairment and dementia. On this basis the overarching aims of the project are: 1) To investigate the common mechanisms involved in the pathogenesis of DR and cognitive impairment in the T2D. 2) To use the retina as a tool to identifying individuals with T2D at a higher risk of developing cognitive decline or dementia. Our multidisciplinary consortium (RECOGNISED) consist of top research leaders in the field belonging to 15 prestigious institutions as well as EATRIS, IDF-Europe and Alzheimer Europe and 3 SMEs. RECOGNISED will apply innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in T2D population and will use this knowledge to characterize clinical phenotypes (personalized medicine) based on retinal functional and structural characteristics and serum biomarkers in order to stratify the risk and severity of cognitive decline. Previously collected data from registries, cohorts and biobanks will be appropriately exploited and robust new data will be generated that will guide clinical recommendations and open up new therapeutic strategies. Ultimately, RECOGNISED project will help to reduce the huge societal and economic burden associated with diabetes-related cognitive impairment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores